解聚酶联合多黏菌素靶向KL160泛耐药鲍曼不动杆菌小鼠菌血症模型
本研究在小鼠菌血症模型中评估噬菌体来源解聚酶DPO-HL单用及联合多黏菌素B治疗KL160泛耐药鲍曼不动杆菌感染的效果。DPO-HL单用仅挽救30%小鼠,而联合治疗(1.45 mg/kg DPO-HL + 0.5 mg/kg多黏菌素B)使生存率达100%,并显著降低内毒素水平。
要点
- DPO-HL靶向KL160荚膜多糖,与多黏菌素B协同使后者MIC降低16倍。
- DPO-HL单用降低细菌载量和内毒素,但仅30%菌血症小鼠存活。
- 联合治疗(1.45 mg/kg DPO-HL + 0.5 mg/kg多黏菌素B)实现100%生存,与给药途径无关。
核心结论
- 本研究鉴定了一种靶向KL160的解聚酶,并证明其与多黏菌素B联合治疗鲍曼不动杆菌菌血症具有强效协同作用,支持其临床应用潜力。
研究设计与样本
- 研究采用小鼠菌血症模型,评估DPO-HL单用及联合多黏菌素B的疗效、安全性和潜在机制;DPO-HL经Ni-NTA亲和色谱表达纯化。
主要发现
- DPO-HL靶向KL160荚膜多糖,在血浆中稳定并增强血浆杀菌效果。
- DPO-HL与多黏菌素B强协同,使多黏菌素B的MIC降低16倍,并有效清除成熟生物膜。
- DPO-HL单用降低细菌载量和内毒素水平,但仅挽救30%菌血症小鼠。
- 联合治疗(1.45 mg/kg DPO-HL + 0.5 mg/kg多黏菌素B)显著降低内毒素水平,无论腹腔还是静脉给药均实现100%生存。
关键数值与推荐
- DPO-HL与多黏菌素B联用使多黏菌素B的MIC降低16倍。
- 联合治疗剂量为1.45 mg/kg DPO-HL + 0.5 mg/kg多黏菌素B。
- DPO-HL单药治疗小鼠生存率为30%。
- 联合治疗小鼠生存率为100%,且与给药途径无关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Acinetobacter baumannii bacteremia caused by pandrug-resistant strains poses a major challenge in intensive care units, necessitating novel therapeutic approaches. Phage-derived depolymerases offer a promising adjunct to conventional antibiotics. However, studies on A. baumannii phage depolymerases have been limited to non-mammalian models. This study investigates the therapeutic efficacy, safety, and potential mechanisms of action of DPO-HL, both as a monotherapy and in combination with polymyxin B, in a murine model of A. baumannii bacteremia. METHODS: DPO-HL was expressed and purified via Ni-NTA affinity chromatography. Its bactericidal activity was assessed through dynamic killing and biofilm disruption assays. Interaction with human plasma was examined to determine its impact on plasma's bactericidal activity. Synergy with polymyxin B was evaluated by MIC reduction. Safety was assessed via cytotoxicity, haemolysis, and acute toxicity tests. A mouse bacteremia model was established to evaluate therapeutic efficacy via intraperitoneal and intravenous administration. RESULTS: DPO-HL, targeting KL160 capsular polysaccharide, exhibited stability in plasma and enhanced plasma's bactericidal effect. It showed strong synergy with polymyxin B, reducing its MIC by 16-fold, and efficiently eradicated mature biofilms. DPO-HL alone reduced bacterial load and endotoxin levels but rescued only 30% of bacteremia mice. Combination therapy (1.45 mg/kg DPO-HL + 0.5 mg/kg polymyxin B) significantly reduced endotoxin levels and achieved 100% survival, regardless of administration route. CONCLUSIONS: This study identifies a KL160-targeting depolymerase and demonstrates its potent synergy with polymyxin B in treating A. baumannii bacteremia, supporting its potential for clinical application.
引用
- Zhang BL, Li H, Wang WX, et al. Depolymerase as a potent adjunct to polymyxin for targeting KL160 pandrug-resistant Acinetobacter baumannii in a murine bacteremia model. J Antimicrob Chemother. 2025. PMID: 40202898. doi:10.1093/jac/dkaf110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。